BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 2726237)

  • 1. [Repeated yearly BCG treatment in superficial bladder cancer].
    Somogyi L; Török A; Bors G; Drinóczy M; Horváth R
    Orv Hetil; 1989 Mar; 130(13):671-3. PubMed ID: 2726237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The immunotherapy of bladder tumors and the immunoprophylaxis of disease recurrence].
    Korovin AI; Savvin VT
    Urol Nefrol (Mosk); 1996; (1):19-21. PubMed ID: 8659034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Radical cystectomy for superficial tumors in the BCG era].
    Huguet Pérez J; Palou J; Millán Rodríguez F; Villavicencio Mavrich H; Rodríguez JV
    Arch Esp Urol; 2002; 55(1):50-6. PubMed ID: 11957752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Results obtained by intravesical instillation of BCG in superficial bladder tumors].
    Romics I; Dietmar B; Christoph R
    Orv Hetil; 1990 Jan; 131(1):25-8. PubMed ID: 2405331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
    Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
    Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The intravesical administration of BCG vaccine in treating recurrent superficial bladder cancer].
    Panteleeva ES; Neprina GS; Vatin OE; Kariakin OB; Safiullin KN
    Urol Nefrol (Mosk); 1997; (2):29-32. PubMed ID: 9206879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravesical administration of bacillus Calmette-Guérin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial.
    Pinsky CM; Camacho FJ; Kerr D; Geller NL; Klein FA; Herr HA; Whitmore WF; Oettgen HF
    Cancer Treat Rep; 1985 Jan; 69(1):47-53. PubMed ID: 3881177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Adjuvant BCG immunotherapy in the management of superficial bladder tumors].
    Somogyi L; Szántó A; Polyák L; Baranyay F; Drinóczy M
    Orv Hetil; 1993 Aug; 134(34):1851-6. PubMed ID: 8355975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immunotherapy of superficial bladder tumors in a hospital department].
    Prekopp G; Rosdy E
    Orv Hetil; 1993 Dec; 134(50):2757-60. PubMed ID: 8265124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
    Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
    Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Results of BCG immunotherapy in the management of bladder tumors].
    Samodai L; Kiss L; Kolozsy Z; Dauda G; Drinóczy M; Mohácsi L
    Orv Hetil; 1990 Aug; 131(31):1697-702. PubMed ID: 2205825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
    Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
    J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long-term results and complications of intravesical instillation of bacillus Calmette-Guerin for prophylaxis of bladder cancer recurrence].
    Irie A; Lee KE; Kadowaki K; Sawamura M
    Hinyokika Kiyo; 1994 Oct; 40(10):873-7. PubMed ID: 7992700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chemo-immunoprevention in superficial bladder cancer].
    Adolphs HD; Bastian HP
    Urologe A; 1986 Jan; 25(1):51-4. PubMed ID: 3962045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The need of prolonged BCG treatment in superficial bladder cancer is suggested by the development of a peripheral immune response induced by BCG].
    Shekarsarai H; Zlotta AR; Drowart A; Van Vooren JP; De Cock M; Pirson M; Palfliet K; Jurion F; Vanonckelen A; Simon J; Schulman CC; Huygen K
    Acta Urol Belg; 1997 Mar; 65(1):1-4. PubMed ID: 9245197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of superficial tumors and carcinomas in situ of the bladder by intravesical BCG therapy].
    Steg A; Leleu C; Boccon-Gibod L; Debré B
    Ann Urol (Paris); 1986; 20(1):26-32. PubMed ID: 3707074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Intravesical bacillus Calmette-Guerin in the treatment of recurrent superficial bladder tumors].
    Nakano M; Iwamuro S; Fujii H; Kondoh I
    Hinyokika Kiyo; 1988 Jun; 34(6):983-6. PubMed ID: 3223463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin.
    Brake M; Loertzer H; Horsch R; Keller H
    J Urol; 2000 Jun; 163(6):1697-701. PubMed ID: 10799163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Intravesical BCG vaccine in bladder cancer].
    Beisland HO; Sander S
    Tidsskr Nor Laegeforen; 1989 Jun; 109(17-18):1891-2. PubMed ID: 2749672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.